Company Snapshot: Prothena Corporation
Prothena Corporation plc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of novel antibodies for the treatment of various diseases associated with protein misfolding or cell adhesion. Its product pipeline includes NEOD001, a product candidate in Phase 1 clinical trial to target AL and AA forms of amyloidosis; PRX002 for the treatment of Parkinsons disease and related synucleinopathies; and PRX003 for the treatment of inflammatory disease and metastatic cancers. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dublin, Ireland.
- Jun 12 2017 Prothena Announces Appointment of Wagner Zago, PhD as Chief Scientific Officer
- May 16 2017 Prothena Announces Appointment of Sarah Noonberg, MD, PhD as Chief Medical Officer
- May 9 2017 Prothena Reports First Quarter 2017 Financial Results and Provides R&D Update
- May 2 2017 Prothena to Report First Quarter 2017 Financial Results on May 9